API | pomaglumetad

pomaglumetad Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Pomaglumetad (LY-404,039) is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II subtypes mGluR2 and mGluR3. Pharmacological research has focused on its potential antipsychotic and anxiolytic effects. Pomaglumetad is intended as a treatment for schizophrenia and other psychotic and anxiety disorders by modulating glutamatergic activity and reducing presynaptic release of glutamate at synapses in limbic and forebrain areas relevant to these disorders. Human studies investigating therapeutic use of pomaglumetad have focused on the prodrug LY-2140023, a methionine amide of pomaglumetad (also called pomaglumetad methionil) since pomaglumetad exhibits low oral absorption and bioavailability in humans. ^Wikipedia

Chemistry

SMILES: CSCC[C@H](N)C(=O)N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(=O)O)C(=O)O
InChIKey: VOYCNOJFAJAILW-CAMHOICYSA-N
Mol. Mass: 366.42
ALogP: -1.87 Partition coefficient
ChEMBL Molecule:
pomaglumetad methionil

More Chemistry

Pharmacology

Mechanisms of Action:
- Metabotropic glutamate receptor 2 (Homo sapiens) ^UniProt
- Metabotropic glutamate receptor 3 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ly2140023 | ly 2140023 | ly-2140023 | ly2140023 monohydrate | pomaglumetad | pomaglumetad methionil

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

Mental Health (Phase 1)

Methamphetamine (Phase 1)

Schizophrenia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 24
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue